Pyrotec PackMark recently reminded pharmaceutical manufacturers who sell their products on the European market about the Falsified Medicines Directive (FMD). Producers will have to comply with this legislation from January 2016.
The second Global Cosmetic Compliance Summit will bring together more than 70 directors of regulatory affairs, heads of compliance and brand owners from an international audience to tackle regulatory challenges across the globe and exploit growth in emerging and existing markets.
On 26 November patent attorney and partner at Spoor Fisher, David Cochrane called the Department of Trade & Industry’s (dti’s) draft policy for Intellectual Property ‘unclear’. Speaking at a media briefing at the Free Market Foundation (FMF), he said the main problem was that the policy was not drafted with input from experts in IP law, which led to uncertainty in meaning, intention and compliance with the agreement on the international Trade-Related Aspects of Intellectual Property Rights (TRIPS) to which South Africa is a signatory.
In the wake of the Department of Trade and Industry’s draft IP policy, Janusz Luterek, patent attorney and director of Hahn & Hahn, sheds light on the current patent law framework in South Africa and the impact the draft policy may have on the pharmaceutical industry should it eventually come into effect.
Complementary and Alternative Medicines (CAMs) are gaining ground in the medical, health and wellness markets in South Africa. However, the sector is increasingly on government’s radar and manufacturers are now facing tougher regulations than ever before.